Arrowhead Pharmaceuticals (ARWR) Earnings Analysis

Arrowhead Pharmaceuticals (ARWR) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it beat with EPS -0.93 USD vs -1.09 USD est (+14.7%). It has beaten estimates in 2/7 recent quarters (29%). Trailing P/E -41.45.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ARWR next report earnings?

No confirmed upcoming earnings date is currently scheduled for ARWR. This page updates as the calendar is published.

ARWR earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.93 USD-1.09 USD+14.7%Beat
2026-02-050.22 USD0.6 USD-63.3%Miss
2025-11-25-0.18 USD-0.11157 USD-61.3%Miss
2025-08-07-1.26 USD-0.94 USD-34%Miss
2025-05-122.75 USD-0.06 USD+4683.3%Beat
2025-02-10-1.39 USD-0.42 USD-231%Miss
2024-11-26-1.38 USD-1.05 USD-31.4%Miss

Beat rate: 2/7 (29%) over reported quarters with consensus data.

ARWR valuation and analyst view

Trailing P/E-41.45
Trailing EPS-2.11289 USD
Price / book20.57
Dividend yield0.00%
Market cap12.70B
Analyst consensusBuy (16 buy / 6 hold / 0 sell)
Avg price target99.17 USD

Related research pages

Frequently asked questions

When is Arrowhead Pharmaceuticals (ARWR)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for ARWR. This page updates as the calendar is published.

Did ARWR beat earnings last quarter?

In its 2026-05-07 report, ARWR posted EPS of -0.93 USD versus a -1.09 USD estimate — a beat of 14.7%.

What is ARWR's earnings track record?

Over the last 7 reported quarters with consensus data, ARWR beat estimates 2 times (29%).

What is ARWR's current P/E ratio and EPS?

ARWR trades at a trailing P/E of -41.45 on trailing EPS of -2.1128938258775287 USD.

What do analysts rate ARWR?

Analyst consensus is "Buy" across 22 ratings (0 strong buy, 16 buy, 6 hold, 0 sell, 0 strong sell). Average 12-month price target: 99.17 USD.